Across TCGA pan-cancer cohorts, FRRS1L mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FRRS1L data layer compared with 23 for mass-spec protein.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher FRRS1L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FRRS1L expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where FRRS1L mass-spec protein most reproducibly stratifies survival.